Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3065 |
|
Actual shortage: | 232 (8%) | |
Anticipated shortage: | 15 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2809 (92%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (12%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2019-02-13 | 2019-03-30 | 75623 |
APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2019-02-24 | 2019-03-29 | 76729 |
APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2019-05-15 | 2019-06-24 | 84128 |
APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2020-02-13 | 2020-06-02 | 106006 |
APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2020-04-13 | 2020-06-02 | 111925 |
APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-06-04 | 2020-07-28 | 116547 |
APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2020-06-24 | 2020-12-17 | 118769 |
APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2020-07-29 | 2020-12-17 | 121334 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2020-07-29 | 2020-12-17 | 121337 |
APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-09-09 | 2020-12-17 | 123957 |
APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2020-10-07 | 2020-12-17 | 125815 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-04-01 | 2022-04-29 | 157701 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-06-06 | 2022-07-11 | 162083 |
APO-OLANZAPINE | 10MG | TABLET | Resolved | 2022-10-07 | 2022-12-05 | 171422 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-10-17 | 2022-12-05 | 171886 |
APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2022-10-28 | 2022-12-09 | 172901 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-01-26 | 2023-02-02 | 182367 |
APO-OLANZAPINE | 10MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184083 |
APO-OLANZAPINE | 20MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184097 |
APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-05-06 | 2023-06-02 | 191874 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |